N

Novartis

Global pharmaceutical company delivering science-based innovations

Radioligand Therapies Ecosystem Lead

Full-Time
$185.5k - $344.5k/yr+ Performance-based cash incentive + Potential annual equity awards
Expert
Bachelor's
San Francisco, CA, USA+2 moreMore locations: San Jose, CA, USA | Sacramento, CA, USA
RemoteMust reside within the territory or within 100 miles of its border; travel 60–80% is required.
Sales & Account ManagementAccount Management
No H1B Sponsorship

About the job

Requirements
  • A bachelor’s degree from a four-year college or university is required.
  • At least 10 years of experience in pharmaceutical, biotech, healthcare, or similarly structured industries with large, geographically dispersed teams; candidates from medical devices, diagnostics, life sciences services, insurance, consumer health, or B2B sectors are also welcomed when field leadership and customer engagement are central to their experience.
  • At least 5 years of account management experience covering Academic Medical Centers, Integrated Health Systems, GPOs, and/or Large Community Oncology Integrated Networks.
  • At least 2 years of project management or leadership experience and successful translation of strategy into execution.
  • At least 2 years of experience leading complex projects requiring cross-functional and national alignment.
  • Recent US experience within the last 5 years, with a deep understanding of the US healthcare ecosystem.
  • A robust business background and demonstrated ability to collaborate, work, and lead cross-functionally in a matrix environment to build and drive strategic account plans aligned with customer and organizational goals.
  • Must reside within the territory or within a reasonable daily commuting distance of 100 miles from the territory border.
  • Ability to travel 60–80% over a broad geography, including driving and/or flying within the territory.
  • Must have a fully valid and unrestricted driver’s license; driving is an essential function of the role.
  • Must complete initial field-role training, including home study, limited to eight hours per day and forty hours per week.
Responsibilities
  • Understand target ecosystem archetype customers at all levels, from departments to the C-suite, and use insights to anticipate and navigate business trends, articulate insights, and drive priorities and outcomes.
  • Develop and drive strategic plans, leading the region’s Integrated Field Strategy Team to advance company objectives and address account needs; collaborate with team members on pre-launch and launch strategy and execution across headquarters, account, and regional executive teams.
  • Build strategic customer relationships with ecosystem partners and identify, prioritize, and champion change opportunities that better serve them.
  • Identify collaboration and engagement opportunities with ecosystem C-suite, D-suite, and other non-healthcare-professional decision-makers; serve as the RLT oncology primary contact and partner with account leads on executive and headquarters exchanges.
  • Create opportunities for internal cross-functional collaboration, mobilize partners across functions to eliminate barriers and create solutions, and lead communication, problem-solving, decision-making, and enterprise-minded collaboration.
  • Provide alternatives and solutions when challenges and ambiguity arise.
  • Own account performance across the RLT platform, identify and lead opportunities to impact demand-generating functions, achieve ecosystem performance, and influence cross-functional teams including sales and access.
  • Establish and enable effective communications between Novartis and ecosystems, internal account teams, customer engagement leadership, and other company functions; anticipate and communicate strategic shifts aligned with organizational goals and encourage teams to adapt and lead confidently.
  • Manage multiple highly critical and complex ecosystem archetype targets.
Desired Qualifications
  • Oncology, Nuclear Medicine, Buy and Bill, or other leading-edge healthcare experience in a highly matrixed organization.
  • Understanding of the macroeconomic landscape in healthcare and its impact on operational, clinical, and financial decisions.

About the company

Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1970

Get referred to Novartis

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ianalumab won FDA Breakthrough Therapy designation on January 16, 2026.
  • Remibrutinib posted positive Phase III data in April 2026 and September 2026.
  • The October 2, 2026 Abogen deal adds optionality across autoimmune RNA programs.

What critics are saying

  • Entresto generic erosion hits in November 2026 after a September 2026 patent-loss setback.
  • Reuters reported two late-stage failures in September 2026 erased nearly $30 billion.
  • Novartis faces India pricing pressure over ribociclib; Kerala High Court scrutiny continues.

What makes Novartis unique

  • Novartis pairs blockbuster execution with 2026 launches like Rhapsido and Itvisma.
  • Its 2026 autoimmune push spans remibrutinib, ianalumab, and Abogen's ABO2203.
  • CAS collaboration in September 2026 strengthens Novartis's AI-ready reaction data advantage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 27th, 2026
Novartis raises 2026 profit guidance as Q3 sales rise 4% to $14.5B

Novartis raised its 2026 profit outlook after a strong third quarter. It now expects core operating income to be in line with last year or up by a low single-digit percentage, versus a previous forecast of a low single-digit decline. Net sales rose 4% in constant currency to $14.5 billion. Core operating income climbed 10% to $6 billion, and core earnings per share grew 8% to $2.46. Priority brands rose 29%, led by Kisqali (up 37%), Leqvio (up 63%), and Scemblix (up 67%). Reported operating income fell 61% to $1.8 billion, mainly because of a $1.9 billion partial impairment of Daldesiran after it missed its primary endpoint in a Phase III trial. Free cash flow was $5.1 billion for the quarter. Novartis has bought back $2.8 billion of shares under a program of up to $10 billion.

Incyte
Oct 24th, 2026
MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab | Incyte

Planegg/Munich, Germany, and Wilmington, Delaware, U.S., January 13, 2020 MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab - MorphoSys and Incyte to co-commercialize tafasitamab in the U.S. - Incyte has exclusive commercialization rights outside of the U.S.

Yahoo Finance
Oct 22nd, 2026
Novartis wins EU approval for Cosentyx in polymyalgia rheumatica, a first for IL-17A inhibitors

Novartis has won European Commission approval for Cosentyx to treat polymyalgia rheumatica in adults. It is the first IL-17A inhibitor cleared in Europe specifically for the condition. The approval rests on Phase III trial data supporting use in patients with limited treatment options. The new indication extends Cosentyx's reach in immunology, a priority area for the Swiss drugmaker, which has a market value of CHF241.2 billion. Analysts flag tighter pricing and reimbursement pressure in Europe as a risk for each added indication.

Asianet News
Oct 17th, 2026
Novartis discontinues mid-stage lupus trial in latest pipeline setback.

Novartis discontinues mid-stage lupus trial in latest pipeline setback. Published: Oct 17 2026, 04:05 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus. * Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy. * Novartis has faced multiple clinical setbacks over the past several weeks, including trial failures and development discontinuations. * According to data from Koyfin, 8 of the 23 analysts rate the stock a 'buy' or 'strong buy,' while 13 rate it a 'hold' and only two rate it 'sell.' Shares of Novartis (NVS) closed little changed on Friday after the company decided to discontinue its mid-stage trial of iptacopan in lupus nephritis. According to a federal clinical trials registry update, the company has concluded the study over 'strategic considerations.' It is unclear if the discontinuation was spurred by efficacy or safety concerns. The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment. The company decided to conclude the study after completing the first part, as per the database. Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy. Latest pipeline setback for Novartis. Novartis has faced multiple clinical setbacks over the past several weeks. Last month, the company said that its late-stage trial of Pelacarsen, being developed as a treatment to lower elevated lipoprotein(a) or Lp(a) and reduce the risk of major cardiovascular events, missed its primary goal. The company also said that its late-stage trial of del-desiran in myotonic dystrophy type 1 (DM1) missed its primary endpoint. Besides the late-stage drug failures, the company also discontinued development of VHB937 in mid-September after a mid-stage study missed primary and secondary goals. Prior to that, in August, Novartis paused multiple autoimmune and neurology trials after three fatal cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) in patients taking its experimental therapy Rap-cel. According to data from Koyfin, 8 of the 23 analysts rate the stock a 'buy' or 'strong buy,' while 13 rate it a 'hold' and only two rate it 'sell.' How did NVS retail traders react? On Stocktwits, retail sentiment around NVS stock stayed within the 'bearish' territory over the past 24 hours, while message volume rose from 'low' to 'normal' levels. NVS stock has gained 9% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com. Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

European Biotechnology
Oct 16th, 2026
Evotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOs.

Evotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOs. Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell European Biotechnology about the companies they join. This week: a swift scientific leadership change at Evotec, a broader reshuffle at Sibylla and a new CEO to guide AL-S Pharma toward Phase 3. Evotec: Joanna Holbrook takes over as CSO. Holbrook will join the management board on Nov. 1, succeeding Cord Dohrmann, who stepped down Sept. 30 by mutual agreement after 16 years in the role. Holbrook joins from Novo Nordisk, where she led research in cardiovascular, renal and hepatic disease as well as in vitro discovery platforms. At Evotec, she will oversee scientific strategy across its discovery and development services and technology platforms. Go deeper. Sibylla Biotech: Four executive changes ahead of the clinic. The Italian biotech named Usman Azam CEO and Gianluca Fuggetta CFO. Azam led CAR-T developer Tmunity Therapeutics for more than five years and previously headed Novartis' cell and gene therapies unit. Sibylla cofounder and former CEO Lidia Pieri becomes COO, while Elena Ardini moves up to CSO. The team will advance Sibylla's lead Cyclin D1 protein degrader toward a first human study. Go deeper. AL-S Pharma: Harry Welten becomes CEO. He succeeds Michael Salzmann as the Swiss biotech prepares a confirmatory Phase 3 trial of AP-101, an antibody targeting misfolded SOD1 in amyotrophic lateral sclerosis. Welten says financing and partnerships will be priorities. The company now aims to start Phase 3 in 2027, a shift from its March target of late 2026. Its earlier Phase 2 study met a primary endpoint focused on safety. Go deeper. Integra Therapeutics: Simon Dew joins to build partnerships. Dew becomes chief business officer at the Barcelona biotech, joining from Macomics after earlier business development roles at several cell and gene therapy companies. Integra wants him to find partners for FiCAT, its preclinical gene-writing platform for cell and gene therapies. The company closed a €10.7 million financing in 2025, intended to validate CAR-T applications and prepare the technology for transfer to pharma partners. Go deeper. TETRAPHARM: Rolf Sass Sørensen succeeds a cofounder. Sørensen became CEO on Oct. 6, replacing Martin Rose. Rose and fellow cofounder Jesper Breum are leaving operational roles to pursue new biotech ventures but remain shareholders. Sørensen, a former Bavarian Nordic investor relations executive, takes over a business combining preclinical drug programs with contract development and manufacturing services. Go deeper. | (C) european biotechnology | Joachim Eeckhout 16 October 2026 |